Long-Acting Versus Standard Non-Ergot Dopamine Agonists in Parkinson's Disease: A Meta-Analysis of Randomized Controlled Trials

Updates in the medical management of Parkinson disease

(2012) H. H. FERNANDEZ   CLEVELAND CLINIC JOURNAL OF MEDICINE

Efficacy and Safety of Extended- Versus Immediate-Release Pramipexole in Japanese Patients With Advanced and L-dopa–Undertreated Parkinson Disease

(2012) Yoshikuni Mizuno et al.   CLINICAL NEUROPHARMACOLOGY

Steady-State Plasma Concentration Profile of Transdermal Rotigotine: An Integrated Analysis of Three, Open-Label, Randomized, Phase I Multiple Dose Studies

(2012) Jan-Peer Elshoff et al.   CLINICAL THERAPEUTICS

Therapies in Parkinsonʼs disease

(2012) Joseph Jankovic et al.   CURRENT OPINION IN NEUROLOGY

Continuous dopaminergic stimulation and novel formulations of dopamine agonists

(2011) Fabrizio Stocchi   JOURNAL OF NEUROLOGY

PREPARED: Comparison of prolonged and immediate release ropinirole in advanced Parkinson's disease

(2011) Fabrizio Stocchi et al.   MOVEMENT DISORDERS

The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists

(2011) Vibeke Guldbrand Rasmussen et al.   MOVEMENT DISORDERS

Extended-release pramipexole in early Parkinson disease: A 33-week randomized controlled trial

(2011) W. Poewe et al.   NEUROLOGY

Extended-release pramipexole in advanced Parkinson disease: A randomized controlled trial

(2011) A. H. V. Schapira et al.   NEUROLOGY

Pharmacokinetics of a Once-Daily extended-release formulation of pramipexole in healthy male volunteers: Three studies

(2010) Peter Jenner et al.   CLINICAL THERAPEUTICS

Tolerability and Safety of Ropinirole versus Other Dopamine Agonists and Levodopa in the Treatment of Parkinsonʼs Disease

(2010) Jaime Kulisevsky et al.   DRUG SAFETY

Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson's disease

(2010) Olivier Rascol et al.   MOVEMENT DISORDERS

Continuous administration of rotigotine to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces dyskinesia induction

(2009) K.A. Stockwell et al.   EXPERIMENTAL NEUROLOGY

Continuous rotigotine administration reduces dyskinesia resulting from pulsatile treatment with rotigotine or l-DOPA in MPTP-treated common marmosets

(2009) K.A. Stockwell et al.   EXPERIMENTAL NEUROLOGY

Adherence to antiparkinson medication in a multicenter European study

(2009) Donald Grosset et al.   MOVEMENT DISORDERS

Pharmacologic treatment of advanced Parkinson's disease: A meta-analysis of COMT inhibitors and MAO-B inhibitors

(2009) Ripple Talati et al.   PARKINSONISM & RELATED DISORDERS

Pharmacokinetic and Pharmacodynamic Comparison of Ropinirole 24-Hour Prolonged Release and Ropinirole Immediate Release in Patients With Parkinson's Disease

(2008) Debra Tompson et al.   CLINICAL NEUROPHARMACOLOGY

Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: a randomized, double-blind, non-inferiority crossover study

(2008) Fabrizio Stocchi et al.   CURRENT MEDICAL RESEARCH AND OPINION

Continuous delivery of ropinirole reverses motor deficits without dyskinesia induction in MPTP-treated common marmosets

(2008) K.A. Stockwell et al.   EXPERIMENTAL NEUROLOGY